TCGA-A2-A0CY-01A-12R-A034-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 56
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.410
- PANCREAS_BETA_CELLS+0.320
- KRAS_SIGNALING_DN+0.290
- HEDGEHOG_SIGNALING+0.250
- HYPOXIA+0.170
- ESTROGEN_RESPONSE_LATE+0.140
- SPERMATOGENESIS+0.130
- GLYCOLYSIS+0.110
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.110
- UNFOLDED_PROTEIN_RESPONSE+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.520
- PROTEIN_SECRETION-0.410
- UV_RESPONSE_DN-0.400
- ALLOGRAFT_REJECTION-0.390
- ANGIOGENESIS-0.390
- IL6_JAK_STAT3_SIGNALING-0.390
- TGF_BETA_SIGNALING-0.370
- MITOTIC_SPINDLE-0.340
- OXIDATIVE_PHOSPHORYLATION-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650159 | — | — | 0.846 |
| 2 | SRR25617838 | — | E | 0.824 |
| 3 | 3e1c728a-cf38-4ca8-9d87-0bbf098567a6 | — | — | 0.797 |
| 4 | 85d43afd-9aac-48ca-a9c4-00357b7207e1 | — | — | 0.794 |
| 5 | MNG538 | — | — | 0.793 |
| 6 | SRR10900550 | — | — | 0.787 |
| 7 | TCGA-39-5027-01A-21R-1820-07 | — | cohortSQ2 | 0.787 |
| 8 | R233 | — | — | 0.786 |
| 9 | SRR25617841 | — | E | 0.781 |
| 10 | TCGA-NC-A5HF-01A-11R-A26W-07 | — | cohortSQ1 | 0.780 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.050 | Inavolisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| MYOGENESIS | 0.010 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |